Avidity Biosciences Inc
RNAM
주식 순위
#2081
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
주가
$71.34
마지막 동기화: 2026-03-03
시가총액
$9.84B
변동 (1일)
0.00%
변동 (1년)
-
국가
US
거래 Avidity Biosciences Inc (RNAM)
카테고리
Healthcare
Avidity Biosciences Inc (RNAM)의 EPS
2026 기준 EPS TTM: 0
Avidity Biosciences Inc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Avidity Biosciences Inc의 EPS 기록 (2018 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2025 | $-4.97 | 71.97% |
| 2024 | $-2.89 | -0.69% |
| 2023 | $-2.91 | -12.87% |
| 2022 | $-3.34 | 17.19% |
| 2021 | $-2.85 | 39.02% |
| 2020 | $-2.05 | 210.61% |
| 2019 | $-0.66 | 120.00% |
| 2018 | $-0.30 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| $13.70 | - |
BE
|
